| Bioactivity | Elranatamab (PF-06863135) is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. Elranatamab targets both BCMA (on myeloma cells) and CD3 (on T cells). Elranatamab activates and directs T cells to induce a cytotoxic T-cell response against myeloma cells. Elranatamab can be used for research of relapsed or refractory multiple myeloma[1]. |
| CAS | 2408850-14-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lesokhin AM, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023 Sep;29(9):2259-2267. |